Teva Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?
TEVA PHARMS has three hundred and eighteen approved drugs.
There are two US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.
There are seventeen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and fourteen supplementary protection certificates in eighteen countries.
Summary for Teva Pharms
International Patents: | 17 |
US Patents: | 2 |
Tradenames: | 264 |
Ingredients: | 259 |
NDAs: | 318 |
Drugs and US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | LEUCOVORIN CALCIUM | leucovorin calcium | INJECTABLE;INJECTION | 081277-001 | Sep 28, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms | EVALOSE | lactulose | SOLUTION;ORAL | 073497-001 | May 28, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms | VALACYCLOVIR HYDROCHLORIDE | valacyclovir hydrochloride | TABLET;ORAL | 077655-002 | May 24, 2010 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms Usa Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | CAPSULE;ORAL | 213256-003 | Jan 6, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharms Intl | SYNRIBO | omacetaxine mepesuccinate | POWDER;SUBCUTANEOUS | 203585-001 | Oct 26, 2012 | RE45128 | ⤷ Try a Trial |
Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 7,199,098 | ⤷ Try a Trial |
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,362,161 | ⤷ Try a Trial |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 8,877,245 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Premature patent expirations for TEVA PHARMS
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Teva Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 03020252 | ⤷ Try a Trial |
Hong Kong | 1143732 | ⤷ Try a Trial |
Japan | 4794816 | ⤷ Try a Trial |
Cyprus | 1109799 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
0454436 | 97C0012 | Belgium | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927 |
2371361 | 2019/055 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; NAT REGISTRATION NO/DATE: EU/1/09/537/001 20090804; FIRST REGISTRATION NO/DATE: EU/1/09/537/001 04/08/2009 (14/10/2020) |
3150586 | PA2020508,C3150586 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KOBICISTATAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.